These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10897206)

  • 1. [Possible clinical application of immunochemotherapy experimented in animals].
    Hosokawa M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):811-6. PubMed ID: 10897206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunological analysis of chemotherapeutic effects for the effective immunochemotherapy against cancer].
    Yamada Y
    Hokkaido Igaku Zasshi; 1984 Nov; 59(6):721-7. PubMed ID: 6397415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Augmentation of antitumor immunity in cancer chemotherapy].
    Hosokawa M; Kobayashi H
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1402-6. PubMed ID: 1697151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New direction in immunochemotherapy of cancer].
    Nitta K
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1117-28. PubMed ID: 6191674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy.
    Zhou H; Sequeira M; Goad ME; Erickson J; Wong A; Clark E; Dunussi-Joannopoulos K; Li RC; Friedrich S; Hayes LL; Wolf SF
    Clin Immunol; 2001 Dec; 101(3):303-14. PubMed ID: 11726223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
    Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modification of suppressor activity and effector activity of tumor-bearing hosts by bleomycin].
    Hosokawa M
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):677-83. PubMed ID: 2421642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel immunotherapeutic modality with direct hemoperfusion targeting transforming growth factor-beta prolongs the survival of tumor-bearing rats.
    Yamamoto Y; Ueda Y; Itoh T; Iwamoto A; Yamagishi H; Shimagaki M; Teramoto K
    Oncol Rep; 2006 Dec; 16(6):1277-84. PubMed ID: 17089050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors.
    Ben-Hur H; Kossoy G; Zandbank J; Zusman I
    Int J Mol Med; 2002 Apr; 9(4):425-30. PubMed ID: 11891540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunodeficiency and cancer: prospects for correction.
    Hadden JW
    Int Immunopharmacol; 2003 Aug; 3(8):1061-71. PubMed ID: 12860163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.
    Gomez GG; Hutchison RB; Kruse CA
    Cancer Treat Rev; 2001 Dec; 27(6):375-402. PubMed ID: 11908930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors.
    Tong Y; Song W; Crystal RG
    Cancer Res; 2001 Oct; 61(20):7530-5. PubMed ID: 11606390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.